201 related articles for article (PubMed ID: 33805264)
41. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
42. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
[TBL] [Abstract][Full Text] [Related]
43.
Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
[TBL] [Abstract][Full Text] [Related]
44. Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System Tumors.
Weich A; Serfling SE; Schlötelburg W; Higuchi T; Hartrampf PE; Schirbel A; Heinrich M; Buck AK; Rowe SP; Kosmala A; Werner RA
Clin Nucl Med; 2023 Jul; 48(7):586-593. PubMed ID: 37167408
[TBL] [Abstract][Full Text] [Related]
45. Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT.
Duell J; Krummenast F; Schirbel A; Klassen P; Samnick S; Rauert-Wunderlich H; Rasche L; Buck AK; Wester HJ; Rosenwald A; Einsele H; Topp MS; Lapa C; Kircher M
J Nucl Med; 2021 Oct; 62(10):1415-1421. PubMed ID: 33579803
[TBL] [Abstract][Full Text] [Related]
46. Imaging of Chemokine Receptor CXCR4 in Mycosis Fungoides Using 68Ga-Pentixafor PET/CT.
Kuyumcu S; Yilmaz E; Büyükkaya F; Özkan ZG; Ünal SN
Clin Nucl Med; 2018 Aug; 43(8):606-608. PubMed ID: 29916918
[TBL] [Abstract][Full Text] [Related]
47. 68 Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results.
Jena SR; Watts A; Aggarwal P; Bachhal V; Kaur H; Dhingra K; Singh H; Bal A; Singh B
Nucl Med Commun; 2024 Mar; 45(3):229-235. PubMed ID: 38165171
[TBL] [Abstract][Full Text] [Related]
48. Response assessment with the CXCR4-directed positron emission tomography tracer [
Herhaus P; Habringer S; Vag T; Steiger K; Slotta-Huspenina J; Gerngroß C; Wiestler B; Wester HJ; Schwaiger M; Keller U
EJNMMI Res; 2017 Dec; 7(1):51. PubMed ID: 28577295
[TBL] [Abstract][Full Text] [Related]
49. [68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary Results.
Mayerhoefer ME; Jaeger U; Staber P; Raderer M; Wadsak W; Pfaff S; Kornauth C; Senn D; Weber M; Wester HJ; Skrabs C; Haug A
Invest Radiol; 2018 Jul; 53(7):403-408. PubMed ID: 29642081
[TBL] [Abstract][Full Text] [Related]
50. Semi-quantitative measurements of chemokine receptor 4-targeted
Pan Q; Cao X; Luo Y; Li J; Li F
EJNMMI Res; 2021 Oct; 11(1):110. PubMed ID: 34714390
[TBL] [Abstract][Full Text] [Related]
51. Imaging the Cytokine Receptor CXCR4 in Atherosclerotic Plaques with the Radiotracer
Hyafil F; Pelisek J; Laitinen I; Schottelius M; Mohring M; Döring Y; van der Vorst EP; Kallmayer M; Steiger K; Poschenrieder A; Notni J; Fischer J; Baumgartner C; Rischpler C; Nekolla SG; Weber C; Eckstein HH; Wester HJ; Schwaiger M
J Nucl Med; 2017 Mar; 58(3):499-506. PubMed ID: 27789718
[No Abstract] [Full Text] [Related]
52. Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas.
Michalski K; Schlötelburg W; Hartrampf P; Heinrich M; Serfling S; Buck AK; Werner RA; Kosmala A; Weich A
Mol Imaging Biol; 2024 Apr; 26(2):344-350. PubMed ID: 38332341
[TBL] [Abstract][Full Text] [Related]
53.
Kesler M; Levine C; Hershkovitz D; Mishani E; Menachem Y; Lerman H; Zohar Y; Shibolet O; Even-Sapir E
J Nucl Med; 2019 Feb; 60(2):185-191. PubMed ID: 30002112
[No Abstract] [Full Text] [Related]
54. 68 Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results.
Waheed A; Singh B; Watts A; Kaur H; Singh H; Dhingra K; Ahuja C; Madan R; Singh A; Radotra BD
Clin Nucl Med; 2024 Apr; 49(4):e141-e148. PubMed ID: 38350065
[TBL] [Abstract][Full Text] [Related]
55. Comparison of (18F)FDG PET/CT and (68Ga)DOTATATE PET/CT imaging methods in terms of detection of histological subtype and related SUVmax values in patients with pulmonary carcinoid tumors.
Komek H; Can C; Urakçi Z; Kepenek F
Nucl Med Commun; 2019 May; 40(5):517-524. PubMed ID: 30694875
[TBL] [Abstract][Full Text] [Related]
56. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
Pan Q; Cao X; Luo Y; Li J; Li F
Clin Nucl Med; 2021 Sep; 46(9):732-737. PubMed ID: 34172595
[TBL] [Abstract][Full Text] [Related]
57. [68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.
Li X; Heber D; Leike T; Beitzke D; Lu X; Zhang X; Wei Y; Mitterhauser M; Wadsak W; Kropf S; Wester HJ; Loewe C; Hacker M; Haug AR
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):558-566. PubMed ID: 28932900
[TBL] [Abstract][Full Text] [Related]
58. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
[TBL] [Abstract][Full Text] [Related]
59. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
60. Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using
Weiberg D; Thackeray JT; Daum G; Sohns JM; Kropf S; Wester HJ; Ross TL; Bengel FM; Derlin T
J Nucl Med; 2018 Feb; 59(2):266-272. PubMed ID: 28775206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]